Saskatchewan patients with a rare form of cystic fibrosis will soon have access to a new oral medication. Beginning September 1, 2014, the province will provide coverage of Kalydeco to treat patients with a rare form of cystic fibrosis.
“This drug can help improve the quality of life and lung function for cystic fibrosis patients,” Health Minister Dustin Duncan said. “Our government is pleased to make this drug more accessible to the patients who need coverage to assist with the substantial cost of Kalydeco.”
Cystic fibrosis is a genetic disease affecting mainly children and young adults. It is a multi-system disease affecting mainly the lungs, as well as the digestive system.
“We applaud the Government of Saskatchewan for its compassionate action in making Kalydeco available to cystic fibrosis patients who need it,” Cystic Fibrosis Canada Vice President of Advocacy, Research and Health care Ken Chan said. “This funding decision will benefit the health and well-being of patients going on this medication.”
Saskatchewan is the third province among Pan-Canadian Pricing Alliance members to provide coverage, following Ontario and Alberta.
In 2013, about 130 cystic fibrosis patients benefited from approved medications listed by the Saskatchewan Drug Plan, at a total cost to the province of about $1.75 million.
Cystic fibrosis patients seeking more information are encouraged to talk with their physicians, or call the Drug Plan and Extended Benefits Branch at 306-787-3317 in Regina or toll free at 1-800-667-7581. Information about the Cystic Fibrosis Program is available online at www.health.gov.sk.ca/sail.